A specific form of the tau protein, called phosphorylated-tau-217 or p-tau217, may function as a blood biomarker of Alzheimer’s disease, allow the development of blood tests to accurately diagnose the disease at earlier stages. These are the findings of three studies presented during the recent Alzheimer’s Association International Conference (AAIC) 2020. The brains of those with Alzheimer’s disease show accumulation of tau protein aggregates, which are thought to precede the loss of nerve cells, shrinkage of the brain, and…
You must be logged in to read/download the full post.
The post Specific Tau Protein Shows Potential as Blood Biomarker in Early Studies appeared first on BioNewsFeeds.